Floatz logo

Solu-Cortef

Overeating

Eleonora SeeligN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Overeating cohort.

Asset / SponsorPhaseRating
Guanfacine
Maimonides Medical Center
Phase 4BB
pf-08653944
Pfizer
Phase 2CCC
pf-08653945
Pfizer
Phase 2CCC
Betahistine
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phase 1CC
Gly-Low
Hoskinson Health and Wellness Clinic
Early Phase 1CC
Metyrapone
Eleonora Seelig
N/AD

Same molecule, other indications

Solu-Cortef is also rated in:

congenital adrenal hyperplasiaDormant
A
Indicative ·
81 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
myelodysplastic syndromeDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →